Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E. Neal, Malcolm D. Mason, Richard J. Bryant et al.|European Urology|2019Cited by 150
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Duncan C. Gilbert et al.|The Lancet|2021Cited by 49
Medication understanding among patients living with multiple chronic conditions: Implications for patient-reported measures of adherenceRob J. Fredericksen, Heidi M. Crane, Laura E. Gibbons et al.|Research in Social and Administrative Pharmacy|2017Cited by 25
Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary CareRob J. Fredericksen, Heidi M. Crane, Kenneth H. Mayer et al.|Journal of General Internal Medicine|2018Cited by 13
Development and content validation of measures assessing adherence barriers and behaviors for use in clinical careRob J. Fredericksen, Heidi M. Crane, Frances M. Yang et al.|Research in Social and Administrative Pharmacy|2018Cited by 9